

7-ALKOXYCOUMARINS AS CYP2C9 SUBSTRATES


This invention relates to compounds, processes for preparing them and their use as enzyme substrates.

5 The majority of metabolism based drug interactions are a result of inhibition of cytochrome P450 enzymes. Drug interactions involving individual P450 enzymes can be predicted using *in vitro* methods. Typical *in vitro* P450 enzyme assays involve incubation of an appropriate substrate with a source of enzyme. Traditionally, time consuming chromatographic methods have been used for metabolite detection in these incubations.
10 More recently the availability of fluorimetric plate readers has facilitated the higher throughput of enzyme assays in general. Adapting P450 assays to fluorescent plate reader technology requires the identification of substrates with appropriate fluorescent products for individual enzymes. Among the xenobiotic-metabolising cytochromes P450, CYP2C9 is one of those commonly responsible for the metabolism of drugs.

15 3-Cyano-7-ethoxycoumarin has been described for high throughput CYP2C9 inhibition screening (Crespi *et al.*, *Anal. Biochem.*, 1997; 248, 188-190). However, the rate of 3-cyano-7-ethoxycoumarin metabolism by CYP2C9 is low and the extent of 3-cyano-7-ethoxycoumarin O-dealkylase inhibition does not always correlate well with a solid-phase extraction assay for CYP2C9, thus 3-cyano-7-ethoxycoumarin is not suitable
20 for high throughput screening.

Certain compounds have now been identified which are improved substrates for CYP2C9 and which are of use for configuring high throughput inhibition screening assays.

25 According to the present invention there is provided an assay for testing for inhibitors of the enzyme CYP2C9 which comprises contacting the enzyme and a compound of formula (I):



(I)

30 wherein R¹ represents C₁₋₂alkyl, with a test compound and measuring inhibition of O-dealkylation of the compound of formula (I) by the enzyme.


In a preferred aspect of the invention R¹ is methyl.

Generally the rate of O-dealkylation of the compound of formula (I) in the absence of test compound will be known, as will the extent of O-dealkylation at given time points.

The assay may test for inhibition of O-dealkylation continuously or at specified time points.

O-Dealkylation of the compound of formula (I) following incubation with CYP2C9 gives a readily quantifiable fluorescent product of formula (II):

5



(II)


which can be scanned with suitable excitation and emission wavelengths, for example an excitation wavelength of 410 nm and an emission wavelength of 510 nm.

10 The assay may be carried out either in solution or utilising a solid support. When the assay is carried out in solution suitable solvents include methanol, acetonitrile and DMSO.

The test compound may be pre-incubated with enzyme prior to the addition of the substrate, or alternatively the substrate may be added simultaneously. Final
15 concentrations of enzyme and substrate are calculated so as to achieve a suitable rate of processing for carrying out the assay. If desired, the reaction may be stopped, for example by addition of acid or solvent. The fluorescent product of formula (II) may be analysed using any conventional system of fluorescence detection, for example a multi-well plate/fluorescent plate reader.

20 The compounds of formula (I) and (II) are novel and as such also form part of the invention.

The compounds of formula (I) and (II) may be prepared by conventional methods, for example as shown in Scheme 1:



Scheme 1

Thus according to a further aspect of the invention there is provided a process for the production of a compound of formula (I) or (II) which comprises:

- a) reaction of resorcinol and a dialkyl trifluoroacetosuccinate wherein the alkyl groups are independently selected from C₁₋₂ alkyl, in the presence of polyphosphoric acid;
- b) for compounds of formula (I) reaction of the resulting 7-hydroxycoumarin with a compound of formula R¹Hal, wherein R¹ is C₁₋₂ alkyl and Hal is halogen e.g. iodine or bromine; and
- c) ester hydrolysis to give the acid of formula (I) or (II).

The reaction of resorcinol with a dialkyl trifluoroacetosuccinate in the presence of polyphosphoric acid may suitably be performed at a temperature of about 15-30°C.

Typical reaction conditions for the alkylation of a 7-hydroxycoumarin with an alkyl halide are well known to those skilled in the art and include a solvent such as acetone at reflux in the presence of a base such as potassium carbonate.

Typical reaction conditions for ester hydrolysis are well known to those skilled in the art and include dilute hydrochloric acid in methanol or ethanol at reflux.

Dialkyl trifluoroacetosuccinates of formula **1** may be prepared from the corresponding alkyl bromoacetate and alkyl trifluoroacetoacetate according to the route described in C. Aubert *et al*, *J. Fluorine Chem.* **1989**, *44*, 361. Suitable alkyl bromoacetates and alkyl trifluoroacetoacetates are commercially available.

5

Since the inhibition of cytochrome P450 enzymes is often the mechanism for drug/drug interactions, the assay according to the invention is particularly useful for identifying compounds which may give rise to adverse drug/drug interactions. The assay can therefore be used in combination with the chemical modification of test compounds to increase a test compound's potential for use as a pharmaceutical.

10

Thus according to further aspects of the invention there are provided a method for reducing the CYP2C9 enzyme inhibitory activity of a compound, comprising the steps of identifying the compound as an inhibitor of CYP2C9 in the assay described above; and thereafter producing a chemically modified version of the test compound in which the functionality suspected to be responsible for CYP2C9 inhibition is eliminated or changed; and novel compounds produced according to this method.

15

The chemical modification of test compounds according to this method can be performed using techniques well known to those skilled in the art.

The novel compounds produced according to this aspect of the invention may find application as pharmaceuticals. A compound produced according to this method will be readily identifiable as novel by performing routine literature and database searches. The pharmaceutical activity of such compounds can be readily ascertained using conventional biological screening methods known to those skilled in the art.

20

All publications, including but not limited to patents and patent applications, cited in this specification are herein incorporated by reference as if each individual publication were specifically and individually indicated to be incorporated by reference herein as though fully set forth.

25

The invention is illustrated by the following examples.

30

Example**Preparation of 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid.**

5

a) 7-Hydroxy-4-trifluoromethyl coumarin-3-acetic acid ethyl ester [**2**, R^a = Et]

Polyphosphoric acid (45 g) was added to a mixture of resorcinol (4.06 g) and diethyl trifluoroacetosuccinate (9.96 g) (Aubert, C.; Begue, J. P.; Charpentier-Morize, M.; Nee, G.; Langlois, B. *J. Fluorine Chem.* **1989**, *44*, 361). The mixture was stirred at room temperature for 24 h. Crushed ice was added and the mixture extracted with dichloromethane. The organic phase was washed with water then dried (MgSO₄) and evaporated. The residue was purified by chromatography on silica gel (eluent 2% methanol in dichloromethane) to give the title compound (1.24 g) m.p. 112.5 - 114.0°C. $\delta_{\text{H}}(\text{CDCl}_3)$ 1.30 (t, 3H), 3.96 (m, 2H), 4.24 (q, 2H), 6.66 (d, $J = 2.5$ Hz, 1H), 6.75 (dd, $J = 9.0, 2.5$ Hz, 1H), 7.55 (m, 1H); mass spectrum m/z 317 (MH⁺).

15

b) 7-Methoxy-4-trifluoromethyl coumarin-3-acetic acid ethyl ester [**3**, R¹ = Me, R^a = Et]

20

Methyl iodide (0.41 ml) was added to a mixture of **2** (0.7 g), potassium carbonate (0.46 g) and acetone (15 ml). The mixture was heated under reflux for 5 h. After cooling the solvent was evaporated and the residue was partitioned between dichloromethane and water. The organic phase was washed with water and then dried (MgSO₄) and evaporated. The residue was purified by chromatography on silica gel (eluent 0.5% methanol in dichloromethane) to give the title compound (0.62 g). $\delta_{\text{H}}(\text{CDCl}_3)$ 1.26 (t, 3H), 3.90 (s, 3H), 3.94 (m, 2H), 4.19 (q, 2H), 6.86 (d, $J = 2.6$ Hz, 1H), 6.91 (dd, $J = 9.2, 2.6$ Hz, 1H), 7.70 (m, 1H); mass spectrum m/z 331 (MH⁺).

25

c) 7-Methoxy-4-trifluoromethyl coumarin-3-acetic acid [(**I**), R¹ = Me]

30

A mixture of **3** (0.615 g), ethanol (5 ml) and dilute hydrochloric acid (3M, 100 ml) was heated under reflux. After 6 h the mixture was cooled and the solid collected by filtration. The dried solid was crystallised from diethyl ether/hexane to give the title compound (0.475 g) m.p. 198.5 - 200.0°C (Found: C, 51.60; H, 2.82. C₁₃H₅F₃O₅ requires C, 51.67; H, 3.00%); $\delta_{\text{H}}(\text{CDCl}_3)$ 3.90 (s, 3H), 3.94 (m, 2H), 6.87 (d, $J = 2.6$ Hz, 1H), 6.92 (dd $J = 9.2, 2.6$ Hz, 1H), 7.70 (m, 1H); mass spectrum m/z 325 (M + Na⁺), 303 (MH⁺), 285 (M - OH⁻).

35

Assay methodology

Materials:

- 5 6.25 mM 7-Methoxy-4-trifluoromethylcoumarin-3-acetic acid (i.e. 1.88
mg/mL in DMSO)
2 % (w/v) NaHCO_3 - stored at approx. 4°C
50 mM potassium phosphate buffer, pH 7.4
Freshly prepared cofactor solution:- approx. the following per mL of 2 %
10 (w/v) NaHCO_3
1.7 mg NADP, monosodium salt
7.8 mg glucose-6-phosphate, monosodium salt
6 Units glucose-6-phosphate dehydrogenase, Type VII from Bakers
Yeast

15

Method:

- 1) Mix 1 μL 6.25 mM 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid, 10 μL (100
20 μg) CYP2C9 microsomal protein and 209 μL buffer per incubate (giving 25 μM 7-
methoxy-4-trifluoromethylcoumarin-3-acetic and 400 $\mu\text{g}/\text{mL}$ protein final
concentration).
- 2) To each well of a 96-well plate add 220 μL of incubation mix and 5 μL of test
25 compound in methanol. (or 5 μL of appropriate solvent for control wells – methanol,
acetonitrile or DMSO may be used).
- 3) Pre-incubate the multi-well plate in the plate reader at 37°C for 5 minutes. Pre-warm
the cofactor solution at 37°C for 5 minutes.
- 30 4) Add 25 μL cofactor solution to each well and scan with an excitation wavelength of
410 nm and an emission wavelength of 510 nm with a gain of 80. Scan for 10 cycles
at 1 minute intervals.

Results

Confirmation of 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as a CYP2C9 substrate was achieved using sulphaphenazole, a diagnostic CYP2C9 inhibitor (Back *et al.* *British Journal of Clinical Pharmacology*, 1988, 26, 23-29). With sulphaphenazole, 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid was inhibited with an IC₅₀ of 0.29 μ M (Figure 1), an inhibition value typical of other, well characterised, CYP2C9 substrates.